{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:44:11Z","timestamp":1793835851869,"version":"4.6.1"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":111,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Research, Development, and Innovation Authority (RDIA) - Kingdom of Saudi Arabia","award":["12899-jazzan-2023-JZU-R-2-1-HW"],"award-info":[{"award-number":["12899-jazzan-2023-JZU-R-2-1-HW"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-026-01502-z","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T07:02:14Z","timestamp":1782370934000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Next-generation mRNA vaccines: strategies to overcome stability challenges"],"prefix":"10.1038","volume":"11","author":[{"given":"Abdullah","family":"Algaissi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivakumar S.","family":"Moni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"1502_CR1","doi-asserted-by":"crossref","first-page":"e20220008","DOI":"10.1002\/INMD.20220008","volume":"1","author":"L Lin","year":"2023","unstructured":"Lin, L., Pei, Y., Li, Z. & Luo, D. Progress and challenges of mRNA vaccines. Interdiscip. Med. 1, e20220008 (2023).","journal-title":"Interdiscip. Med."},{"key":"1502_CR2","doi-asserted-by":"crossref","first-page":"1326154","DOI":"10.3389\/fpubh.2023.1326154","volume":"11","author":"DA Montero","year":"2023","unstructured":"Montero, D. A. et al. Two centuries of vaccination: historical and conceptual approach and future perspectives. Front. Public Health 11, 1326154 (2023).","journal-title":"Front. Public Health"},{"key":"1502_CR3","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bj.2023.01.002","volume":"46","author":"KM Lee","year":"2023","unstructured":"Lee, K. M., Lin, S. J., Wu, C. J. & Kuo, R. L. Race with virus evolution: the development and application of mRNA vaccines against SARS-CoV-2. Biomed. J. 46, 70\u201380 (2023).","journal-title":"Biomed. J."},{"key":"1502_CR4","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.3390\/ijms24032700","volume":"24","author":"V Gote","year":"2023","unstructured":"Gote, V., Bolla, P. K., Kommineni, N., Butreddy, A., Nukala, P. K., Palakurthi, S. S. & Khan, W. A comprehensive review of mRNA vaccines. Int. J. Mol. Sci. 24, 2700 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1502_CR5","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41392-023-01579-1","volume":"8","author":"G Zhang","year":"2023","unstructured":"Zhang, G., Tang, T., Chen, Y., Huang, X. & Liang, T. mRNA vaccines in disease prevention and treatment. Signal Transduct. Target Ther. 8, 365 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"1502_CR6","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1002\/mco2.167","volume":"3","author":"Y Gu","year":"2022","unstructured":"Gu, Y., Duan, J., Yang, N., Yang, Y. & Zhao, X. mRNA vaccines in the prevention and treatment of diseases. MedComm. 3, e167 (2022).","journal-title":"MedComm."},{"key":"1502_CR7","doi-asserted-by":"crossref","first-page":"1332939","DOI":"10.3389\/fimmu.2024.1332939","volume":"15","author":"B Lu","year":"2024","unstructured":"Lu, B. et al. The next-generation DNA vaccine platforms and delivery systems: advances, challenges and prospects. Front. Immunol. 15, 1332939 (2024).","journal-title":"Front. Immunol."},{"key":"1502_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12929-024-01080-z","volume":"31","author":"RM Lu","year":"2024","unstructured":"Lu, R. M. et al. Current landscape of mRNA technologies and delivery systems for new modality therapeutics. J. Biomed. Sci. 31, 89 (2024).","journal-title":"J. Biomed. Sci."},{"key":"1502_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40794-025-00246-3","volume":"11","author":"K Batisani","year":"2025","unstructured":"Batisani, K. The role of mRNA vaccines in infectious diseases: a new era of immunization. Trop. Dis. Travel Med. Vaccines 11, 12 (2025).","journal-title":"Trop. Dis. Travel Med. Vaccines"},{"key":"1502_CR10","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3390\/pharmaceutics14020430","volume":"14","author":"Z Kis","year":"2022","unstructured":"Kis, Z. Stability modelling of mRNA vaccine quality based on temperature monitoring throughout the distribution chain. Pharmaceutics 14, 430 (2022).","journal-title":"Pharmaceutics"},{"key":"1502_CR11","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3390\/vaccines9091033","volume":"9","author":"MN Uddin","year":"2021","unstructured":"Uddin, M. N. & Roni, M. A. Challenges of storage and stability of mRNA-based COVID-19 vaccines. Vaccines 9, 1033 (2021).","journal-title":"Vaccines"},{"key":"1502_CR12","volume":"15","author":"ML Fahrni","year":"2022","unstructured":"Fahrni, M. L. et al. Management of COVID-19 vaccines cold chain logistics: a scoping review. J. Pharm. Policy Pract. 15, 16 (2022).","journal-title":"J. Pharm. Policy Pract."},{"key":"1502_CR13","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.xphs.2022.11.001","volume":"112","author":"E Oude Blenke","year":"2023","unstructured":"Oude Blenke, E. et al. The storage and in-use stability of mRNA vaccines and therapeutics: not a cold case. J. Pharm. Sci. 112, 386\u2013403 (2023).","journal-title":"J. Pharm. Sci."},{"key":"1502_CR14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.copbio.2016.03.002","volume":"42","author":"AB Hill","year":"2016","unstructured":"Hill, A. B., Kilgore, C., McGlynn, M. & Jones, C. H. Improving global vaccine accessibility. Curr. Opin. Biotechnol. 42, 67\u201373 (2016).","journal-title":"Curr. Opin. Biotechnol."},{"key":"1502_CR15","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.egyr.2021.12.039","volume":"8","author":"NA Pambudi","year":"2022","unstructured":"Pambudi, N. A., Sarifudin, A., Gandidi, I. M. & Romadhon, R. Vaccine cold chain management and cold storage technology to address the challenges of vaccination programs. Energy Rep. 8, 955\u2013972 (2022).","journal-title":"Energy Rep."},{"key":"1502_CR16","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3390\/vaccines9010065","volume":"9","author":"MD Buschmann","year":"2021","unstructured":"Buschmann, M. D., Carrasco, M. J., Alishetty, S., Paige, M., Alameh, M. G. & Weissman, D. Nanomaterial delivery systems for mRNA vaccines. Vaccines 9, 65 (2021).","journal-title":"Vaccines"},{"key":"1502_CR17","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.3390\/pharmaceutics15071972","volume":"15","author":"N Al Fayez","year":"2023","unstructured":"Al Fayez, N. et al. Recent Advancement in mRNA vaccine development and applications. Pharmaceutics 15, 1972 (2023).","journal-title":"Pharmaceutics"},{"key":"1502_CR18","doi-asserted-by":"crossref","first-page":"e70414","DOI":"10.1002\/mco2.70414","volume":"6","author":"X Li","year":"2025","unstructured":"Li, X. et al. Design strategies for novel lipid nanoparticle for mRNA vaccine and therapeutics: current understandings and future perspectives. MedComm. 6, e70414 (2025).","journal-title":"MedComm."},{"key":"1502_CR19","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1021\/acs.biomac.5c01899","volume":"27","author":"OT Choy","year":"2026","unstructured":"Choy, O. T. et al. PEG-free lipid nanoparticles for mRNA delivery: superhydrophilic sulfoxide polymer coatings. Biomacromolecules 27, 624\u2013639 (2026).","journal-title":"Biomacromolecules"},{"key":"1502_CR20","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.3390\/pharmaceutics16101346","volume":"16","author":"V Karunnanithy","year":"2024","unstructured":"Karunnanithy, V. et al. Effectiveness of lyoprotectants in protein stabilization during lyophilization. Pharmaceutics 16, 1346 (2024).","journal-title":"Pharmaceutics"},{"key":"1502_CR21","doi-asserted-by":"crossref","first-page":"942","DOI":"10.3390\/v16060942","volume":"16","author":"MFH Khan","year":"2024","unstructured":"Khan, M. F. H., Youssef, M., Nesdoly, S. & Kamen, A. A. Development of robust freeze-drying process for long-term stability of rVSV-SARS-CoV-2 vaccine. Viruses 16, 942 (2024).","journal-title":"Viruses"},{"key":"1502_CR22","doi-asserted-by":"crossref","first-page":"10603","DOI":"10.3390\/ijms251910603","volume":"25","author":"T Alejo","year":"2024","unstructured":"Alejo, T. et al. Comprehensive optimization of a freeze-drying process achieving enhanced long-term stability and in vivo performance of lyophilized mRNA-LNPs. Int. J. Mol. Sci. 25, 10603 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"1502_CR23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3390\/vaccines12010065","volume":"12","author":"Y Liu","year":"2024","unstructured":"Liu, Y. et al. Screening and stability evaluation of freeze-dried protective agewents for a live recombinant Pseudorabies virus vaccine. Vaccines 12, 65 (2024).","journal-title":"Vaccines"},{"key":"1502_CR24","doi-asserted-by":"publisher","unstructured":"Zhou, W. et al. Vaccines\u2019 new Era-RNA vaccine. Viruses 15 https:\/\/doi.org\/10.3390\/v15081760 (2023).","DOI":"10.3390\/v15081760"},{"key":"1502_CR25","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s41573-024-01042-y","volume":"23","author":"N Pardi","year":"2024","unstructured":"Pardi, N. & Krammer, F. mRNA vaccines for infectious diseases\u2014advances, challenges and opportunities. Nat. Rev. Drug Discov. 23, 838\u2013861 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1502_CR26","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12985-025-02645-6","volume":"22","author":"KY Leong","year":"2025","unstructured":"Leong, K. Y., Tham, S. K. & Poh, C. L. Revolutionizing immunization: a comprehensive review of mRNA vaccine technology and applications. Virol. J. 22, 71 (2025).","journal-title":"Virol. J."},{"key":"1502_CR27","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41392-024-02002-z","volume":"9","author":"Y Shi","year":"2024","unstructured":"Shi, Y., Shi, M., Wang, Y. & You, J. Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications. Signal Transduct. Target Ther. 9, 322 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"1502_CR28","doi-asserted-by":"crossref","first-page":"103458","DOI":"10.1016\/j.drudis.2022.103458","volume":"28","author":"AAA Aljabali","year":"2023","unstructured":"Aljabali, A. A. A. et al. Current state of, prospects for, and obstacles to mRNA vaccine development. Drug Discov. Today 28, 103458 (2023).","journal-title":"Drug Discov. Today"},{"key":"1502_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51411-9","volume":"15","author":"S Kim","year":"2024","unstructured":"Kim, S. et al. Innate immune responses against mRNA vaccine promote cellular immunity through IFN-\u03b2 at the injection site. Nat. Commun. 15, 7226 (2024).","journal-title":"Nat. Commun."},{"key":"1502_CR30","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","volume":"55","author":"R Verbeke","year":"2022","unstructured":"Verbeke, R., Hogan, M. J., Lor\u00e9, K. & Pardi, N. Innate immune mechanisms of mRNA vaccines. Immunity 55, 1993\u20132005 (2022).","journal-title":"Immunity"},{"key":"1502_CR31","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3390\/vaccines13040389","volume":"13","author":"A Paczkowska","year":"2025","unstructured":"Paczkowska, A. et al. The application of mRNA technology for vaccine production\u2014current state of knowledge. Vaccines 13, 389 (2025).","journal-title":"Vaccines"},{"key":"1502_CR32","unstructured":"https:\/\/www.aha.org\/system\/files\/media\/file\/2021\/03\/infographic-vaccine-storage.pdf (2021)."},{"key":"1502_CR33","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3390\/v15030668","volume":"15","author":"F Cheng","year":"2023","unstructured":"Cheng, F. et al. Research advances on the stability of mRNA vaccines. Viruses 15, 668 (2023).","journal-title":"Viruses"},{"key":"1502_CR34","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.xphs.2023.11.023","volume":"113","author":"U Chheda","year":"2024","unstructured":"Chheda, U., Pradeepan, S., Esposito, E., Strezsak, S., Fernandez-Delgado, O. & Kranz, J. Factors affecting stability of RNA - temperature, length, concentration, pH, and buffering species. J. Pharm. Sci. 113, 377\u2013385 (2024).","journal-title":"J. Pharm. Sci."},{"key":"1502_CR35","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jconrel.2021.05.021","volume":"335","author":"KJ Hassett","year":"2021","unstructured":"Hassett, K. J. et al. Impact of lipid nanoparticle size on mRNA vaccine immunogenicity. J. Control. Release 335, 237\u2013246 (2021).","journal-title":"J. Control. Release"},{"key":"1502_CR36","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1007\/s00018-010-0277-y","volume":"67","author":"Q Kong","year":"2010","unstructured":"Kong, Q. & Lin, C. L. G. Oxidative damage to RNA: mechanisms, consequences, and diseases. Cell Mol. Life Sci. 67, 1817\u20131829 (2010).","journal-title":"Cell Mol. Life Sci."},{"key":"1502_CR37","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3390\/vaccines9020081","volume":"9","author":"I Knezevic","year":"2021","unstructured":"Knezevic, I., Liu, M. A., Peden, K., Zhou, T. & Kang, H.-N. Development of mRNA vaccines: scientific and regulatory issues. Vaccines 9, 81 (2021).","journal-title":"Vaccines"},{"key":"1502_CR38","doi-asserted-by":"crossref","first-page":"11953","DOI":"10.1016\/j.biopha.2021.111953","volume":"142","author":"JT Granados-Riveron","year":"2021","unstructured":"Granados-Riveron, J. T. & Aquino-Jarquin, G. Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2. Biomed. Pharmacother. 142, 11953 (2021).","journal-title":"Biomed. Pharmacother."},{"key":"1502_CR39","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.3390\/biom14081036","volume":"14","author":"N Parvin","year":"2024","unstructured":"Parvin, N., Joo, S. W. & Mandal, T. K. Enhancing vaccine efficacy and stability: a review of the utilization of nanoparticles in mRNA vaccines. Biomolecules 14, 1036 (2024).","journal-title":"Biomolecules"},{"key":"1502_CR40","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.1007\/s10311-021-01256-1","volume":"19","author":"D Ramakanth","year":"2021","unstructured":"Ramakanth, D., Singh, S., Maji, P. K., Lee, Y. S. & Gaikwad, K. K. Advanced packaging for distribution and storage of COVID-19 vaccines: a review. Environ. Chem. Lett. 19, 3597\u20133608 (2021).","journal-title":"Environ. Chem. Lett."},{"key":"1502_CR41","first-page":"100453","volume":"11","author":"X Sun","year":"2021","unstructured":"Sun, X., Andoh, E. A. & Yu, H. A simulation-based analysis for effective distribution of COVID-19 vaccines: a case study in Norway. Transp. Res. Interdiscip. Perspect. 11, 100453 (2021).","journal-title":"Transp. Res. Interdiscip. Perspect."},{"key":"1502_CR42","doi-asserted-by":"publisher","DOI":"10.1039\/D5BM01635E","author":"Z Zhang","year":"2026","unstructured":"Zhang, Z., Ong, Y. H., Yang, B., Fan, B., Yang, Y. Y. & Ni, Q. Chemical engineering strategies to enhance mRNA-LNP stability for therapeutic applications. Biomater. Sci. https:\/\/doi.org\/10.1039\/D5BM01635E (2026).","journal-title":"Biomater. Sci."},{"key":"1502_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00732-9","volume":"8","author":"M Li","year":"2023","unstructured":"Li, M. et al. Lyophilization process optimization and molecular dynamics simulation of mRNA-LNPs for SARS-CoV-2 vaccine. npj Vaccines 8, 153 (2023).","journal-title":"npj Vaccines"},{"key":"1502_CR44","doi-asserted-by":"crossref","first-page":"e2402936","DOI":"10.1002\/advs.202402936","volume":"11","author":"Y Gong","year":"2024","unstructured":"Gong, Y., Yong, D., Liu, G., Xu, J., Ding, J. & Jia, W. A novel self-amplifying mRNA with decreased cytotoxicity and enhanced protein expression by macrodomain mutations. Adv. Sci. 11, e2402936 (2024).","journal-title":"Adv. Sci."},{"key":"1502_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.matt.2024.09.012","author":"M Lu","year":"2024","unstructured":"Lu, M., Xing, H., Zhao, X., Huang, Y., Zheng, A. & Liang, X.-J. Engineered extracellular vesicles as a next-generation vaccine platform. Matter https:\/\/doi.org\/10.1016\/j.matt.2024.09.012 (2024).","journal-title":"Matter"},{"key":"1502_CR46","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3390\/pharmaceutics17060797","volume":"17","author":"AAA Hassan","year":"2025","unstructured":"Hassan, A. A. A., Ramadan, E., Krist\u00f3, K., Regdon, G. Jr. & Sov\u00e1ny, T. Lipid-polymer hybrid nanoparticles as a smart drug delivery system for peptide\/protein delivery. Pharmaceutics 17, 797 (2025).","journal-title":"Pharmaceutics"},{"key":"1502_CR47","doi-asserted-by":"crossref","first-page":"1091797","DOI":"10.3389\/fimmu.2022.1091797","volume":"13","author":"Y Bai","year":"2022","unstructured":"Bai, Y., Liu, D., He, Q., Liu, J., Mao, Q. & Liang, Z. Research progress on circular RNA vaccines. Front. Immunol. 13, 1091797 (2022).","journal-title":"Front. Immunol."},{"key":"1502_CR48","doi-asserted-by":"crossref","first-page":"12884","DOI":"10.3390\/ijms232112884","volume":"23","author":"D Papukashvili","year":"2022","unstructured":"Papukashvili, D., Rcheulishvili, N., Liu, C., Ji, Y., He, Y. & Wang, P. G. Self-amplifying RNA approach for protein replacement therapy. Int. J. Mol. Sci. 23, 12884 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1502_CR49","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3390\/vaccines12030318","volume":"12","author":"N Silva-Pilipich","year":"2024","unstructured":"Silva-Pilipich, N., Beloki, U., Salaberry, L. & Smerdou, C. Self-amplifying RNA: a second revolution of mRNA vaccines against COVID-19. Vaccines 12, 318 (2024).","journal-title":"Vaccines"},{"key":"1502_CR50","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ymthe.2023.10.024","volume":"32","author":"R Malla","year":"2024","unstructured":"Malla, R., Srilatha, M., Farran, B. & Nagaraju, G. P. mRNA vaccines and their delivery strategies: A journey from infectious diseases to cancer. Mol. Ther. 32, 13\u201331 (2024).","journal-title":"Mol. Ther."},{"key":"1502_CR51","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41392-023-01561-x","volume":"8","author":"D Niu","year":"2023","unstructured":"Niu, D., Wu, Y. & Lian, J. Circular RNA vaccine in disease prevention and treatment. Signal Transduct. Target Ther. 8, 341 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"1502_CR52","first-page":"28","volume":"09","author":"Y Zhang","year":"2025","unstructured":"Zhang, Y. et al. Programmable aptamer-embedded circular RNAs for targeted antigen-presenting cells immunotherapy. BioRxiv 09, 28 (2025).","journal-title":"BioRxiv"},{"key":"1502_CR53","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-025-04296-4","author":"AF Aththar","year":"2025","unstructured":"Aththar, A. F. et al. Palm oil nanoemulsion enhances tocotrienol stability, antioxidant, and selective anti-melanoma activity. Naunyn-Schmiedeberg\u2019s Archi. Pharmacol https:\/\/doi.org\/10.1007\/s00210-025-04296-4 (2025).","journal-title":"Naunyn-Schmiedeberg\u2019s Archi. Pharmacol"},{"key":"1502_CR54","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3390\/md20040237","volume":"20","author":"Y Chen","year":"2022","unstructured":"Chen, Y., He, N., Yang, T., Cai, S., Zhang, Y., Lin, J., Huang, M., Chen, W., Zhang, Y. & Hong, Z. Fucoxanthin loaded in palm stearin- and cholesterol-based solid lipid nanoparticle-microcapsules, with improved stability and bioavailability in vivo. Mar. Drugs 20, 237 (2022).","journal-title":"Mar. Drugs"},{"key":"1502_CR55","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3390\/ijms26020726","volume":"26","author":"A Srinivasan","year":"2025","unstructured":"Srinivasan, A., Mroczko-M\u0142otek, E. & Wojciechowska, M. Circular RNA formation and degradation are not directed by universal pathways. Int. J. Mol. Sci. 26, 726 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"1502_CR56","doi-asserted-by":"crossref","first-page":"105127","DOI":"10.1016\/j.isci.2022.105127","volume":"25","author":"N Kommineni","year":"2022","unstructured":"Kommineni, N., Butreddy, A., Sainaga Jyothi, V. G. S. & Angsantikul, P. Freeze-drying for the preservation of immunoengineering products. iScience 25, 105127 (2022).","journal-title":"iScience"},{"key":"1502_CR57","doi-asserted-by":"crossref","first-page":"1567116","DOI":"10.3389\/fimmu.2025.1567116","volume":"16","author":"RA El Arab","year":"2025","unstructured":"El Arab, R. A. et al. Artificial intelligence in vaccine research and development: an umbrella review. Front. Immunol. 16, 1567116 (2025).","journal-title":"Front. Immunol."},{"key":"1502_CR58","doi-asserted-by":"crossref","first-page":"106998","DOI":"10.1016\/j.mimet.2024.106998","volume":"224","author":"DB Olawade","year":"2024","unstructured":"Olawade, D. B. et al. Leveraging artificial intelligence in vaccine development: a narrative review. J. Microbiol. Methods 224, 106998 (2024).","journal-title":"J. Microbiol. Methods"},{"key":"1502_CR59","doi-asserted-by":"crossref","first-page":"1357217","DOI":"10.3389\/fimmu.2024.1357217","volume":"15","author":"A Kumar","year":"2024","unstructured":"Kumar, A., Dixit, S., Srinivasan, K., Dinakaran, M. & Vincent, P. M. D. Personalized cancer vaccine design using AI-powered technologies. Front. Immunol. 15, 1357217 (2024).","journal-title":"Front. Immunol."},{"key":"1502_CR60","doi-asserted-by":"crossref","first-page":"100686","DOI":"10.1016\/j.jvacx.2025.100686","volume":"25","author":"A Aduugna","year":"2025","unstructured":"Aduugna, A. et al. Artificial intelligence-based epitope discovery of Mpox virus: rational vaccine design. Vaccine X 25, 100686 (2025).","journal-title":"Vaccine X"},{"key":"1502_CR61","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/vaccines12010009","volume":"12","author":"SK Niazi","year":"2024","unstructured":"Niazi, S. K. Anti-idiotypic mRNA vaccine to treat autoimmune disorders. Vaccines 12, 9 (2024).","journal-title":"Vaccines"},{"key":"1502_CR62","doi-asserted-by":"crossref","first-page":"100082","DOI":"10.1016\/j.hpopen.2022.100082","volume":"3","author":"MM Hossain","year":"2022","unstructured":"Hossain, M. M., Abdulla, F. & Rahman, A. Challenges and difficulties faced in low- and middle-income countries during COVID-19. Health Policy Open 3, 100082 (2022).","journal-title":"Health Policy Open"},{"key":"1502_CR63","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.3390\/vaccines10081306","volume":"10","author":"LNH Md Khairi","year":"2022","unstructured":"Md Khairi, L. N. H., Fahrni, M. L. & Lazzarino, A. I. The race for global equitable access to COVID-19 vaccines. Vaccines 10, 1306 (2022).","journal-title":"Vaccines"},{"key":"1502_CR64","doi-asserted-by":"crossref","first-page":"2020529","DOI":"10.1080\/21645515.2021.2020529","volume":"18","author":"G Kumraj","year":"2022","unstructured":"Kumraj, G., Pathak, S., Shah, S., Majumder, P., Jain, J., Bhati, D., Hanif, S., Mukherjee, S. & Ahmed, S. Capacity building for vaccine manufacturing across developing countries: the way forward. Hum. Vaccines Immunother. 18, 2020529 (2022).","journal-title":"Hum. Vaccines Immunother."},{"key":"1502_CR65","doi-asserted-by":"crossref","first-page":"344","DOI":"10.2471\/BLT.24.291388","volume":"102","author":"D Dutt","year":"2024","unstructured":"Dutt, D., Mazzucato, M. & Torreele, E. An mRNA technology transfer programme and economic sustainability in health care. Bull. World Health Organ 102, 344\u2013351 (2024).","journal-title":"Bull. World Health Organ"},{"key":"1502_CR66","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3390\/vaccines13020112","volume":"13","author":"ADJLD Abreu","year":"2025","unstructured":"Abreu, A. D. J. L. D. et al. Investment opportunities for mRNA technology in low- and middle-income countries: Key findings and future perspectives. Vaccines 13, 112 (2025).","journal-title":"Vaccines"},{"key":"1502_CR67","doi-asserted-by":"crossref","first-page":"127271","DOI":"10.1016\/j.vaccine.2025.127271","volume":"59","author":"RK Suri","year":"2025","unstructured":"Suri, R. K., Maugeais, D. & Maithal, K. COVID-19 pandemic: a multidimensional analysis and the strategic role played by developing countries vaccine manufacturers. Vaccine 59, 127271 (2025).","journal-title":"Vaccine"},{"key":"1502_CR68","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12951-025-03800-5","volume":"24","author":"Y Quan","year":"2026","unstructured":"Quan, Y., Yang, H., Li, W. & Li, L. mRNA vaccines: immunogenicity and quality characteristics. J. Nanobiotechnol. 24, 6 (2026).","journal-title":"J. Nanobiotechnol."},{"key":"1502_CR69","doi-asserted-by":"crossref","first-page":"120586","DOI":"10.1016\/j.ijpharm.2021.120586","volume":"601","author":"L Schoenmaker","year":"2021","unstructured":"Schoenmaker, L., Witzigmann, D., Kulkarni, J. A., Verbeke, R., Kersten, G., Jiskoot, W. & Crommelin, D. J. A. mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. Int J. Pharm. 601, 120586 (2021).","journal-title":"Int J. Pharm."},{"key":"1502_CR70","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1007\/s00216-018-0943-8","volume":"410","author":"L Baronti","year":"2018","unstructured":"Baronti, L. et al. A guide to large-scale RNA sample preparation. Anal. Bioanal. Chem. 410, 3239\u20133252 (2018).","journal-title":"Anal. Bioanal. Chem."},{"key":"1502_CR71","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1038\/s41596-024-01134-4","volume":"20","author":"Y Ma","year":"2025","unstructured":"Ma, Y., VanKeulen-Miller, R. & Fenton, O. S. mRNA lipid nanoparticle formulation, characterization and evaluation. Nat. Protoc. 20, 2618\u20132651 (2025).","journal-title":"Nat. Protoc."},{"key":"1502_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-52685-1","volume":"14","author":"GB Schober","year":"2024","unstructured":"Schober, G. B., Story, S. & Arya, D. P. A careful look at lipid nanoparticle characterization: analysis of benchmark formulations for encapsulation of RNA cargo size gradient. Sci. Rep. 14, 2403 (2024).","journal-title":"Sci. Rep."},{"key":"1502_CR73","doi-asserted-by":"crossref","unstructured":"Jung, H. N., Lee, S.-Y., Lee, S., Youn, H., Im, H.-J. Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of in vivo imaging. Theranostics 12 7509\u20137531 https:\/\/www.thno.org\/v12p7509","DOI":"10.7150\/thno.77259"},{"key":"1502_CR74","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou, X., Zaks, T., Langer, R. & Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078\u20131094 (2021).","journal-title":"Nat. Rev. Mater."},{"key":"1502_CR75","doi-asserted-by":"crossref","first-page":"4729","DOI":"10.1007\/s13346-025-01866-0","volume":"15","author":"J Duffr\u00e8ne","year":"2025","unstructured":"Duffr\u00e8ne, J. et al. Post-encapsulation methods for the preparation of mRNA-LNPs. Drug Deliv. Transl. Res. 15, 4729\u20134741 (2025).","journal-title":"Drug Deliv. Transl. Res."},{"key":"1502_CR76","doi-asserted-by":"crossref","first-page":"24928","DOI":"10.1021\/acs.analchem.5c03644","volume":"97","author":"AL Espinar","year":"2025","unstructured":"Espinar, A. L., Le Ru, E. C., Kumar, P., Soares, F., O\u2019Driscoll, C. M., Darby, B. L. & Kowalski, P. S. Scatter-free UV\u2013visible spectroscopy for accurate and precise RNA quantification in complex RNA nanoparticle formulations. Anal. Chem. 97, 24928\u201324935 (2025).","journal-title":"Anal. Chem."},{"key":"1502_CR77","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41565-024-01847-3","volume":"20","author":"SRJ Hofstraat","year":"2025","unstructured":"Hofstraat, S. R. J. et al. Nature-inspired platform nanotechnology for RNA delivery to myeloid cells and their bone marrow progenitors. Nat. Nanotechnol. 20, 532\u2013542 (2025).","journal-title":"Nat. Nanotechnol."},{"key":"1502_CR78","doi-asserted-by":"crossref","first-page":"125272","DOI":"10.1016\/j.ijpharm.2025.125272","volume":"650","author":"A Ruppl","year":"2025","unstructured":"Ruppl, A., Neidlein, L., Buchholz, M., Schlensak, C., Friess, W. & Kissmann, J. Formulation screening of lyophilized mRNA lipid nanoparticles for improved stability. Int. J. Pharm. 650, 125272 (2025).","journal-title":"Int. J. Pharm."},{"key":"1502_CR79","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s43094-023-00551-8","volume":"9","author":"SR Pardeshi","year":"2023","unstructured":"Pardeshi, S. R. et al. Process development and quality attributes for the freeze-drying process in pharmaceuticals, biopharmaceuticals and nanomedicine delivery: a state-of-the-art review. Futur J. Pharm. Sci. 9, 99 (2023).","journal-title":"Futur J. Pharm. Sci."},{"key":"1502_CR80","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.3390\/polym14194195","volume":"14","author":"T Liu","year":"2022","unstructured":"Liu, T., Tian, Y., Zheng, A. & Cui, C. Design Strategies for and Stability of mRNA\u2013Lipid Nanoparticle COVID-19 Vaccines. Polymers 14, 4195 (2022).","journal-title":"Polymers"},{"key":"1502_CR81","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1208\/s12249-022-02282-0","volume":"23","author":"J Musakhanian","year":"2022","unstructured":"Musakhanian, J., Rodier, J. D. & Dave, M. Oxidative stability in lipid formulations: a review of the mechanisms, drivers, and inhibitors of oxidation. AAPS PharmSciTech 23, 151 (2022).","journal-title":"AAPS PharmSciTech"},{"key":"1502_CR82","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3390\/vaccines9030267","volume":"9","author":"DJA Crommelin","year":"2021","unstructured":"Crommelin, D. J. A., Anchordoquy, T. J., Volkin, D. B., Jiskoot, W. & Mastrobattista, E. Addressing the cold reality of mRNA vaccine stability. Vaccines 9, 267 (2021).","journal-title":"Vaccines"},{"key":"1502_CR83","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.3390\/vaccines11071224","volume":"11","author":"N Patel","year":"2023","unstructured":"Patel, N., Davis, Z., Hofmann, C., Vlasak, J., Loughney, J. W., DePhillips, P. & Mukherjee, M. Development and characterization of an in vitro cell-based assay to predict potency of mRNA\u2013LNP-based vaccines. Vaccines 11, 1224 (2023).","journal-title":"Vaccines"},{"key":"1502_CR84","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.3390\/vaccines12111234","volume":"12","author":"R Shivji","year":"2024","unstructured":"Shivji, R., Grabski, E. & Jekerle, V. Scientific and regulatory lessons learnt on building a chemistry, manufacturing, and controls (CMC) package for COVID-19 variant vaccine updates in the EU\u2014A regulator\u2019s perspective. Vaccines 12, 1234 (2024).","journal-title":"Vaccines"},{"key":"1502_CR85","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/s11033-026-11455-0","volume":"53","author":"CJA Nowak","year":"2026","unstructured":"Nowak, C. J. A. et al. Process and analytical strategies for the safe production of mRNA vaccines and therapeutics. Mol. Biol. Rep. 53, 306 (2026).","journal-title":"Mol. Biol. Rep."},{"key":"1502_CR86","doi-asserted-by":"crossref","first-page":"1426129","DOI":"10.3389\/fmolb.2024.1426129","volume":"11","author":"R Lenk","year":"2024","unstructured":"Lenk, R., Kleindienst, W., Szab\u00f3, G. T., Baiersd\u00f6rfer, M., Boros, G., Keller, J. M., Mahiny, A. J. & Vlatkovic, I. Understanding the impact of in vitro transcription byproducts and contaminants. Front. Mol. Biosci. 11, 1426129 (2024).","journal-title":"Front. Mol. Biosci."},{"key":"1502_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2025.11.023","author":"X Xu","year":"2025","unstructured":"Xu, X., Cui, L., Zhang, Y. & Gu, J. Deciphering the biological fate of mRNA-LNP-based biologics: a perspective from tissue to intracellular distribution. Acta Pharm. Sin. B https:\/\/doi.org\/10.1016\/j.apsb.2025.11.023 (2025).","journal-title":"Acta Pharm. Sin. B"},{"key":"1502_CR88","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3390\/nano16040268","volume":"16","author":"A Nomani","year":"2026","unstructured":"Nomani, A. et al. Identifying key factors affecting mRNA\u2013lipid nanoparticles drug product formulation stability. Nanomaterials 16, 268 (2026).","journal-title":"Nanomaterials"},{"key":"1502_CR89","doi-asserted-by":"crossref","first-page":"6445","DOI":"10.1021\/acs.nanolett.4c06643","volume":"25","author":"H Tanaka","year":"2025","unstructured":"Tanaka, H. et al. A post-encapsulation method for the preparation of mRNA-LNPs via the nucleic acid-bridged fusion of mRNA-free LNPs. Nano Lett. 25, 6445\u20136453 (2025).","journal-title":"Nano Lett."},{"key":"1502_CR90","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1021\/acsomega.5c10266","volume":"11","author":"CW Jarand","year":"2026","unstructured":"Jarand, C. W., Deng, Z., Brader, M. L. & Reed, W. F. Consequences of mRNA secondary structure on stability against both hydrolysis and aggregation: The role of electrostatic, \u03c0-\u03c0 stacking, and thermal effects. ACS Omega 11, 4440\u20134456 (2026).","journal-title":"ACS Omega"},{"key":"1502_CR91","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3390\/jfb14090437","volume":"14","author":"S Jain","year":"2023","unstructured":"Jain, S. et al. Lipid\u2013polymer hybrid nanosystems: a rational fusion for advanced therapeutic delivery. J. Funct. Biomater. 14, 437 (2023).","journal-title":"J. Funct. Biomater."},{"key":"1502_CR92","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3390\/vaccines13060588","volume":"13","author":"M Eslami","year":"2025","unstructured":"Eslami, M. et al. Next-generation vaccine platforms: Integrating synthetic biology, nanotechnology and systems immunology for improved immunogenicity. Vaccines 13, 588 (2025).","journal-title":"Vaccines"},{"key":"1502_CR93","volume":"13","author":"Y Li","year":"2023","unstructured":"Li, Y. et al. mRNA vaccine in cancer therapy: current advance and future outlook. Clin. Transl. Med. 13, e1384 (2023).","journal-title":"Clin. Transl. Med."},{"key":"1502_CR94","doi-asserted-by":"crossref","first-page":"1029069","DOI":"10.3389\/fimmu.2022.1029069","volume":"13","author":"YL Vishweshwaraiah","year":"2022","unstructured":"Vishweshwaraiah, Y. L. & Dokholyan, N. V. mRNA vaccines for cancer immunotherapy. Front. Immunol. 13, 1029069 (2022).","journal-title":"Front. Immunol."},{"key":"1502_CR95","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/biochem5020005","volume":"5","author":"H Kong","year":"2025","unstructured":"Kong, H. Advances in personalized cancer vaccine development: AI applications from neoantigen discovery to mRNA formulation. BioChem. 5, 5 (2025).","journal-title":"BioChem."},{"key":"1502_CR96","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.3390\/cells14181476","volume":"14","author":"S Zoroddu","year":"2025","unstructured":"Zoroddu, S. & Bagella, L. Next-generation mRNA vaccines in melanoma: advances in delivery and combination strategies. Cells 14, 1476 (2025).","journal-title":"Cells"},{"key":"1502_CR97","doi-asserted-by":"crossref","first-page":"970","DOI":"10.3390\/vaccines13090970","volume":"13","author":"M Magoola","year":"2025","unstructured":"Magoola, M. & Niazi, S. K. Engineering universal cancer immunity: non-tumor-specific mRNA vaccines trigger epitope spreading in cold tumours. Vaccines 13, 970 (2025).","journal-title":"Vaccines"},{"key":"1502_CR98","doi-asserted-by":"crossref","first-page":"101053","DOI":"10.1016\/j.eclinm.2021.101053","volume":"39","author":"PJ Hotez","year":"2021","unstructured":"Hotez, P. J. et al. Global public health security and justice for vaccines and therapeutics in the COVID-19 pandemic. eClinicalMedicine 39, 101053 (2021).","journal-title":"eClinicalMedicine"},{"key":"1502_CR99","doi-asserted-by":"crossref","first-page":"10400","DOI":"10.1093\/nar\/gkae711","volume":"52","author":"S Qi","year":"2024","unstructured":"Qi, S., Wang, H., Liu, G., Qin, Q., Gao, P. & Ying, B. Efficient circularization of protein-encoding RNAs via a novel cis-splicing system. Nucleic Acids Res. 52, 10400\u201310415 (2024).","journal-title":"Nucleic Acids Res."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01502-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01502-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01502-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T07:49:46Z","timestamp":1791964186000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01502-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":99,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1502"],"URL":"https:\/\/doi.org\/10.1038\/s41541-026-01502-z","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"15 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"192"}}